<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this study was to analyse whether <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) may precede and modify the characteristics of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="1" pm="."><plain>Out of the total 362 SLE patients in our service, 223 patients had <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL), of whom 110 met the criteria of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In 26 cases (7.2%) PAPS appeared 5.5 years before the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> (PAPS+SLE Group) </plain></SENT>
<SENT sid="3" pm="."><plain>Their clinical findings were compared to <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> patients without (SLE only Group, n = 26) and with secondary APS (SLE+SAPS Group, n = 26) </plain></SENT>
<SENT sid="4" pm="."><plain>The prevalence of <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>/<z:hpo ids='HP_0002326'>TIA</z:hpo>, recurrent fetal loss, <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> was significantly higher in PAPS+SLE Group as compared to SLE only Group </plain></SENT>
<SENT sid="5" pm="."><plain>The difference in prevalence of fetal loss (P = 0.014) between PAPS+SLE and SLE+SAPS Groups was also recorded </plain></SENT>
<SENT sid="6" pm="."><plain>On comparison to PAPS+SLE Group, patients without APS (SLE only Group) were younger at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>, with more frequent flares and a higher prevalence of WHO type III/IV <z:hpo ids='HP_0000123'>nephritis</z:hpo> (P = 0.007), requiring higher doses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> started in the form of PAPS in 7.2% of our SLE patients, who presented with more thrombotic and less inflammatory complications than in SLE patients without a prior or with a following secondary APS </plain></SENT>
<SENT sid="8" pm="."><plain>Considering the long latency between the two diseases, PAPS may be a forerunner of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>, but it may also coexist with SLE as an independent <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> </plain></SENT>
</text></document>